Explore the legal clash between 180-day exclusivity and authorized generics. Understand how brand-name strategies impact generic profits and patient costs.
The FDA Office of Generic Drugs ensures safe, affordable generic medications reach patients by reviewing applications, enforcing bioequivalence standards, and managing global supply chains under GDUFA and Hatch-Waxman laws.
Paragraph IV certifications let generic drug makers legally challenge brand-name patents before market entry. This Hatch-Waxman Act tool saves billions annually by forcing patent disputes into court, rewarding first challengers with 180 days of exclusivity.
The first generic drug manufacturer to enter the market after a patent expires captures up to 80% of sales during its 180-day exclusivity-and often holds 30-40% years later due to pharmacy and prescriber loyalty.
